Immuneering Corp [IMRX] stock prices are up 0.37% to $5.36 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IMRX shares have gain 15.52% over the last week, with a monthly amount drifted -9.31%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immuneering Corp [NASDAQ: IMRX] stock has seen the most recent analyst activity on October 31, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $15. Previously, Morgan Stanley downgraded its rating to Underweight on December 13, 2024. On March 15, 2024, Needham reiterated its Buy rating and revised its price target to $15 on the stock. TD Cowen downgraded its rating to a Market Perform. Jefferies downgraded its rating to a Hold and reduced its price target to $3 on March 15, 2024. Needham started tracking with a Buy rating for this stock on December 01, 2023, and assigned it a price target of $20.
The stock price of Immuneering Corp [IMRX] has been fluctuating between $1.10 and $10.08 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Immuneering Corp [NASDAQ: IMRX] shares were valued at $5.36 at the most recent close of the market. An investor can expect a potential return of 291.79% based on the average IMRX price forecast.
Analyzing the IMRX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.73 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Immuneering Corp [NASDAQ:IMRX]’s Current Ratio is 24.00. In addition, the Quick Ratio stands at 24.00 and the Cash Ratio stands at 23.84.
Transactions by insiders
Recent insider trading involved Brakewood Harold Eugene, Chief Business Officer, that happened on Jan 16 ’26 when 5250.0 shares were purchased. Director, Schall Thomas J. completed a deal on Jan 15 ’26 to buy 21645.0 shares. Meanwhile, CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought 2298.0 shares on Jan 15 ’26.
